Is Sarda Proteins overvalued or undervalued?

As of January 6, 2025, Sarda Proteins Ltd. is considered overvalued with a "risky" rating due to high financial ratios, including a PE Ratio of 22.60 and a Price to Book Value of 9.54, despite a strong 1-year return of 62.51%.

As of 6 January 2025, Sarda Proteins Ltd. has moved from a grade of "does not qualify" to "risky," indicating a shift in its valuation outlook. The company appears to be overvalued based on its current financial ratios. The PE Ratio stands at 22.60, while the Price to Book Value is significantly high at 9.54, and the EV to Sales ratio is 21.29, all suggesting that the stock price may not be justified by its earnings or asset value.<BR><BR>In comparison to its peers, Sarda Proteins' PE ratio is higher than the industry average, which raises concerns about its valuation. Notably, its EV to EBITDA is -22.57, indicating negative earnings before interest, taxes, depreciation, and amortization, which is a significant red flag. While the company has outperformed the Sensex with a 1-year return of 62.51% compared to the Sensex's 7.57%, this performance may not be sustainable given the current valuation metrics. Overall, Sarda Proteins appears to be overvalued in the current market environment.

What is the technical trend for Sarda Proteins?

As of May 20, 2025, Sarda Proteins shows a mildly bullish trend with mixed signals from indicators like the MACD, Bollinger Bands, and RSI, suggesting caution despite the current price being at a 52-week high of 137.45.

As of 20 May 2025, the technical trend for Sarda Proteins has changed from bullish to mildly bullish. The weekly MACD and Bollinger Bands indicate a bullish stance, while the monthly RSI shows bearish momentum. Daily moving averages remain bullish, supporting the current price of 137.45, which is at a 52-week high. The KST is mildly bearish on a weekly basis but bullish monthly, and Dow Theory reflects a mildly bullish outlook in both time frames. Overall, the strength of the bullish trend is tempered by mixed signals in the RSI and KST, suggesting caution despite the positive indicators.

When is the next results date for Sarda Proteins?

The next results date for Sarda Proteins is 29 November 2025.

The next results date for Sarda Proteins is scheduled for 29 November 2025.

How has been the historical performance of Sarda Proteins?

Sarda Proteins has shown significant sales growth, with net sales rising from 1.30 Cr in Mar'24 to 24.19 Cr in Mar'25, but faced challenges with increased expenditures, resulting in marginal operating profit and a decrease in profit after tax and EPS. Overall, while sales and total assets have grown, profitability remains a concern.

Answer:<BR>The historical performance of Sarda Proteins shows significant fluctuations in its financial metrics over the years.<BR><BR>Breakdown:<BR>Sarda Proteins experienced a notable increase in net sales, rising from 1.30 Cr in Mar'24 to 24.19 Cr in Mar'25, following a trend of varying sales figures over the previous years. The total operating income also reflected this growth, reaching 24.19 Cr in Mar'25 compared to 1.30 Cr in the prior year. However, the company faced challenges with total expenditure, which increased to 24.17 Cr in Mar'25 from 1.44 Cr in Mar'24. This resulted in a marginal operating profit of 0.02 Cr in Mar'25, a slight improvement from the losses recorded in earlier years. The profit before tax remained stable at 0.02 Cr for both Mar'25 and Mar'24, while profit after tax showed a decrease to 0.01 Cr in Mar'25 from 0.02 Cr in Mar'24. The earnings per share (EPS) also reflected this trend, decreasing to 0.06 in Mar'25 from 0.12 in Mar'24. On the balance sheet, total assets increased to 2.53 Cr in Mar'25 from 2.30 Cr in Mar'24, driven by a rise in short-term loans and advances. Overall, while Sarda Proteins has shown growth in sales and total assets, profitability metrics indicate ongoing challenges.

Should I buy, sell or hold Sarda Proteins?

Which are the latest news on Sarda Proteins?

Why is Sarda Proteins Ltd falling/rising?

As of 24-Dec, Sarda Proteins Ltd's stock price is at 82.11, showing a decline after five days of gains and underperforming its sector by 4.98%. The company faces weak long-term fundamentals, including a negative EBITDA and low profitability, contributing to its current stock decline.

As of 24-Dec, Sarda Proteins Ltd is experiencing a decline in its stock price, currently at 82.11, unchanged from the previous day. The stock has underperformed its sector by 4.98% and has shown a trend reversal, falling after five consecutive days of gains. Today, it opened with a loss of 5%, reaching an intraday low of Rs 82.11. The stock has not traded on one day out of the last 20 days, indicating erratic trading behavior. Additionally, there has been a significant drop in investor participation, with delivery volume falling by 98.68% compared to the five-day average. <BR><BR>The company's long-term fundamental strength is weak, as evidenced by a poor EBIT to Interest ratio of -0.01, indicating difficulties in servicing its debt. Furthermore, the Return on Equity stands at a low 3.34%, reflecting low profitability per unit of shareholders' funds. The stock is considered risky due to a negative EBITDA and has generated no return over the past year, with profits decreasing by 11%. These factors collectively contribute to the stock's current decline.

Why is Sarda Proteins Ltd falling/rising?

As of 25-Dec, Sarda Proteins Ltd's stock price is Rs 82.11, reflecting a 5% loss and a 4.98% underperformance against its sector. The company faces significant challenges, including a poor ability to service debt and declining profitability, contributing to the stock's downward trend.

As of 25-Dec, Sarda Proteins Ltd is experiencing a decline in its stock price. The current price is Rs 82.11, with no change from the previous trading session. The stock has underperformed its sector by 4.98% today and opened with a loss of 5%. Additionally, it touched an intraday low of Rs 82.11, indicating a significant drop from its previous levels.<BR><BR>The stock has also shown a trend reversal, having fallen after five consecutive days of gains. This decline is compounded by erratic trading, as it did not trade on one day out of the last 20 days. Furthermore, there has been a notable decrease in investor participation, with delivery volume dropping by 98.68% against the five-day average. <BR><BR>From a fundamental perspective, the company faces challenges, including a weak ability to service its debt, as indicated by a poor EBIT to Interest ratio of -0.01. The Return on Equity is low at 3.34%, signifying low profitability per unit of shareholders' funds. Additionally, the company has reported a negative EBITDA and a decline in profits by 11% over the past year, which further contributes to the stock's riskiness and the current downward trend.